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Objective: To study the effect of long-term treatment ofthe platelet inhibitor ticlopidine as secondary prevention against 
the need of vascular surgery in patients with intermittent claudication. 
Design: The Swedish Ticlopidine Multicentre Study (STIMS), was conducted in six medical and surgical clinics of 
university hospitals in Sweden. 
Methods: 687 claudicants were randomised toticlopidine 250rag bd or placebo and vascular surgery events were recorded 
prospectively over a 7-year period. Cox proportional hazards models of risk for leg vascular surgery were constructed using 
drug treatment and 11 putative risk factors for vascular disease as covariates. Surgical event-free survivals were compared 
by Kaplan-Meier analysis. 
Results: The overall rate of irst operations was 2.4% per annum. More than half of these operations were in the aortoiliac 
region. One-quarter ofpatients operated during the period required further operations but amputation was rare. Ticlopidine 
treatment reduced the need for vascular reconstructive surgery by about half, both in intention-to-treat and on-treatment 
analyses (unadjusted relative risks 0.486, 95% CI 0.317-0.745: p<O.O01; 0.493, 95% CI 0.290-0.841: p<O.01, 
respectively). In Cox model analysis only male sex was confirmed as a risk factor for surgery. Previous peripheral rterial 
surgery was the strongest predictor of the need for surgery. None of the risk factors examined interacted statistically with 
the effect of treatment with ticlopidine. 
Conclusion: In patients with intermittent claudication it seems possible to prevent the need for future vascular surgery 
by the use of platelet inhibition with ticlopidine. 
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In the Swedish Ticlopidine Multicentre Study 
(STIi~S) 1"2 a large group of patients with athero- 
sclerosis characterised by intermittent daudication 
and reduced ankle/arm blood pressure index was 
treated with multiple interventions, including rando- 
raised allocation of the platelet aggregation i hibitory 
R 3 drug ticlopidine hydrochloride (Ticlid), 250 rag bd, 
or placebo. The primary events of the study were 
cardiac or cerebral vascular events and total mortality: 
ticlopidine was found to reduce the incidence of such 
events, chiefly through an effect on cardiac mortality. 
It is now clear that antiplatelet treatment reduces 
*For members ofthe STIMS Group, please see acknowledgements. 
Please address all correspondence to: Prof. D. Bergqvist, Depart- 
ment of Surgery, University Hospital 5751 85 Uppsala, Sweden. 
the risk of acute thrombotic events in a variety of 
circumstances. 4-7Whether or not antiplatelet reat- 
ment can reduce the need for peripheral vascular 
surgery in a risk population is not known for certain. 
In a recent publication from the U.S. Physicians' 
Health Study there is clear evidence that aspirin does 
reduce the need for arterial surge~, s which is con- 
sistent with earlier evidence that aspirin reduces the 
rate of progression of atherosclerotic vessel occlusion 
9 in leg arteries. The aim of this report is two-fold. First, 
the secondary effect of ticlopidine treatment of claudi- 
cants on the requirement for vascular surgery is 
described. Second, information concerning the risks 
for vascular surgery and amputation during long-term 
management of patients with claudication is 
presented. 
1078-5884/95/010069 + 08 $08.00/0 © 1995 W. B. Saunders Company Ltd. 
70 D. Bergqvist et aL 
Table la,b. Study outcomes - Vascular surgical events(a) Intention-to-treat 
Class of vascular surgery 
First event All events 
in study period in study period 
Placebo Ticlopidine Placebo Ticlopidine 
Number of Patients 
Total treatment group 341 346 341 346 
No surgery 284 303 284 303 
Missing surgery code 0 1" 0 1" 
Number of events 
1 Aortoiliac region 33 18 56 28 
2 Femorodistal region 13 7 31 17 
Total reconstructive events 46 a 25 ~ 87 45 
3 Thrombectomy 4 3 15 17 
4 Other surgery related to 1, 2 or 3 3 8 8 17 
6 Amputation of lower limb at any level 0 2 8 7 
Total eg surgical events 53 b 38 b 118 86 
5 Non-leg peripheral vascular surgery 4t 3 4 3 
7 Coronary artery surgery 0 1 0 1 
Total vascular surgical events 57 c 42 c 122 90 
% 2 = 7.27;p <0.01;b X2 = 3.11;p <0.10;cxz = 2.92; 
patients has subsequent type 1 or type 6 operations. 
(b) On-treatment 
p < 0.10.* Missing data counted as an event for statistical nalyses J-Two of these 
Class of vascular surgery 
First event 
in study period 
All events 
in study period 
Placebo Ticlopidine Placebo Ticlopidine 
Total treatment group 339 341 
No surgery 293 309 
Missing surgery code 0 1" 
1 Aortoiliac region 29 12 
2 Femorodistal region 10 4 
Total reconstructive events 39 a 16 a 
3 Thrombectomy 1 3 
4 Other surgery related to 1, 2 or 3 2 6 
6 Amputation of lower limb at any level 0 2 
Total eg surgical events 42 b 27 b 
5 Nonqeg peripheral vascular surgery 4-t 3 
7 Coronary artery surgery 0 1 
Total vascular surgical events 46 ~ 31 ° 




























a%2 = 10.61;p = 0.001;b 9(2 = 3.73;0.10 > p > 0.05;c%2 = 3.40; 0.10 > p 
Missing data counted as an event for statistical nalyses. 
tTwo of these patients has subsequent type 1 or type 6 operations. 
> 0.05.* 
Methods 
Patient population and database 
The pat ient popu la t ion  has been described in detail  
elsewhere, 1 part icular ly as regards the comparabi l i ty  
of leg disease between the treatment groups. 2 Briefly, 
687 patients wi th  intermittent  c laudicat ion as a result 
of per ipheral  arterial d i sease  were randomised  to 
receive t ic lopidine hydrochlor ide (TiclidR-250 mg tab- 
lets, bd) or placebo tablets according to a stratif ied 
min imisat ion  procedure: t reatment extended for up to 
7 years (median observat ion per iod from entry to the 
common trial terminat ion date 5.6 years). Many  of the 
pat ients entered were already part ic ipat ing in man-  
agement  programmes for control by  diet or drugs of 
hypertens ion,  hyperglycaemia ( insu l in -dependent  
diabetics were excluded from the study) and  hyper-  
l ip idaemia and for advice on smok ing  cessation and  
exercise. Patients newly  identi f ied for the study were 
entered into these programmes and all were regular ly 
rev iewed dur ing  up  to 7 years fol low-up, inc lud ing  
quarter ly clinic visits. Causes of death, non-fatal  
myocardia l  infarctions and  strokes, transient 
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ischaemic attack, vascular surgery, amputations and 
adverse vents were recorded together with the results 
of regular laboratory investigations. 
Stratification variables included presence or 
absence of previous leg vascular surgery: these data 
were verified before the randomisation code was 
broken only for those patients recorded as having had 
surgery. The surgical records of all patients were 
reviewed again without reference to the drug alloca- 
tion some time after the code had been broken and the 
principal analyses completed. In this process, aimed at 
verifying and classifying the surgical interventions, 
several events (c. 5% of the total) not recorded 
prospectively were acquired. This process also led to a 
small number of changes of stratification category 
for risk factor analysis, 1° for example because surgery 
had taken place between screening and randomisa- 
tion. Those events that occurred after premature 
cessation of study medication (approximately one- 
third of patients) were also acquired, so that both 
"on-treatment" (OT) and "intention-to-treat" (ITT) 
analyses were possible. Patients were regarded as 
taking study medication and events were counted as 
being "on treatment" unless the patient had been 
formally withdrawn because of death, a vascular 
thrombotic event, adverse event or non-compliance; 
patients interrupting medication temporarily for any 
reason, e.g. to undergo elective surgery, were counted 
as continuously on treatment. Median treatment peri- 
ods were 4.8 years for placebo and 4.0 years for 
ticlopidine. In the OT analysis, events and patients at 
risk were censored from the date of formal 
withdrawal. 
Classification of the surgical and endovascular 
procedures was made without knowledge of the 
allocated treatment according to the following 
scheme: 
Type 1: reconstruction i the aortoiliacofemoral 
region (bifurcation graft; femorofemoral cross-over 
bypass; unilateral reconstructive graft or thromboen- 
darterectomy of the iliac system); 
Type 2: femorodistal bypass, either leg; 
Type 3: thrombectomy in relation to previous 
interventions of Types 1 or 2, either leg; 
Type 4: other peripheral vascular surgery, includ- 
ing angioplasty, related to previous interventions of 
Types 1, 2 or 3, either leg; 
Type 5: other peripheral vascular surgery not 
related to the legs, such as renovascular or carotid 
surgery; 
Type 6: amputation, either leg, at any level; 
Type 7: coronary artery surgery. 
Data analysed 
The outcome data used for these present analyses are 
given in Table la (for intention-to-treat analyses 
--ITT, all patients included) and Table lb (for on- 
treatment analysis--OT, patients who never received 
medication and end-points which occurred more than 
15 days after treatment was first discontinued were 
excluded). The patients' complicance to the therapy 
was controlled by regular tablet counting. The varia- 
bles (covariates) examined for predictive power were 
glycaemia, cholesterolaemia, blood pressure, smoking 
status, duration of local disease (each three levels), 
gender, evidence of coronary artery disease, previous 
leg vascular surger~ triglyceridaemia (each two lev- 
els), white cell count and age (continuous variables). 
Slightly different strata cut-offs were used in this 
analysis than were used for randomisation: the actual 
values used appear in the footnotes to Table 3. White 
cell counts were not recorded at entry for approx- 
imately 20% of the patients and so (in order not to lose 
a large amount of data from the final Cox model) the 
median of all available ntry data has been assigned to 
each patient with a missing value. A few blood 
glucose values were missing but the remaining varia- 
bles were recorded for stratification i  the randomisa- 
tion and were verified before the study was unblin- 
ded: these data sets are complete. 
Methods of analysis 
All statistical methods used are contained within the 
Statistical Analysis System (SAS) 11 or Biomedical Data 
Package (BMDP) ~2 statistical packages. The predictive 
power of each covariate (relative risk for each level) 
for time to outcome was examined by Cox propor- 
tional hazards model methods. Study treatment was 
included as one covariate in order to obtain adjusted 
estimates of treatment effect and (using log-rank X 2 
testing of times to outcome within each level of the 
risk variable) a view of the extent of interaction on 
estimates of treatment effect by other risk variables. 
Probability values derived from the models are unad- 
justed and should be interpreted in the context of the 
multiple comparisons made. Surgery-free survival 
(Kaplan-Meier) plots were also constructed. 
Results 
Overall and on an ITT basis, 2.4% of patients per 
annum, required vascular surgical interventions on 
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the legs. The rate was higher in patients who had had 
leg arterial vascular surgery before entry into the 
study (4.2% pa) than for those who had not (1.5% pa: 
X 2 -- 33.97; d.f. 2; p < 0.001). Kaplan-Meier plots for 
first operations illustrate that the drug effect is 
sustained and uniform over the whole treatment 
period of up to 7 years (Figs. la, b). The operations 
analysed are summarised in Table la, b (ITT and OT 
populations respectively) and include both first and 
subsequent operations carried out during the relevant 
periods. In Table 2a, the requirements for further 
surgical intervention on each leg are set out. Ninety- 
three patients (13.2%) underwent leg vascular surgery 
at some time during the study period. For comparison, 
33% of patients had had leg vascular surgery or 
amputation before entry into the study. One hundred 
legs were operated on with 33 requiring further 
interventions. This is to be compared with the 32% of 
legs operated before the start of the study period 
which required further interventions. Fourteen of 468 
patients who had not had surgery before entry and 19 
of the 219 patients who had been operated before 
entry underwent sequences of operations on the same 
100 
90 ....... ~ - - l__  





30 Key: Ticlopidine 
20 - -  Placebo I 
I 10 
0~- I  I , I , [ I I I I , I I i I I I t I i I I I K [ , I I 
0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 
Month 
100 ....... ~ .... 







~" 30 Key: 
Ticlopidine 
20 .... Placebo 
10 
I I I I I I I I [ I t , I I I I i I I , ] I I I [ I I I 
0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 
Month 
Fig. 1. Kaplan-Meier plots of the proportions ofpatients (ordinate) 
who had not undergone l g vascular surgery (types 1, 2, 3, 4 or 5) at 
each time after andomisation (abscissa). (a) All events occurring up 
to the determined end of study medication (31.12.1978 or prior 
death -- intention-to-treat analysis). (b) Events occurring and 
patients at risk only while taking study medication (on-treatment 
analysis). 
leg during the study period: 16% of sequences ended 
with amputation compared with the 5.3% of operation 
sequences which had ended with amputation before 
entry into the study. 
By univariate analysis, ticlopidine treatment 
reduced the requirement for reconstructive surgery of 
leg arteries by over 50% (relative risks 0.486, 95% 
confidence interval 0.317-0.745, p = 0.0009 ITT; 0.493, 
0.290-0.841, p = 0.0093, OT. 
Risk factors 
Each of the baseline characteristics considered as 
putative risk factors for atherothrombotic events was 
entered into a Cox model regression analysis to assess 
possible influence on outcomes. All of the 11 factors 
chosen gave interpretably narrow confidence intervals 
for the relative risk estimate. Analysis of outcomes 
with these 11 factors and treatment gave the estimates 
of risk shown in Table 3. Interactions between the 11 
covariates and study treatment effect were examined 
within the ITT and OT sets of data: none even 
approached conventional significance. Alternatively 
expressed, the variations in ticlopidine ffect between 
covariate strata are not, within the limitations of size 
of the study, statistically significant and are probably 
clinically insignificant. It is also therefore unlikely that 
any conjunction of major risk factors could explain the 
treatment effect. Adjustment of the estimate of treat- 
ment effect (by the Cox model methods) for baseline 
risk factors suggests more significant action with a 
reduction of requirement for surgery of more than 
55% (Table 3). The adjusted survival curves diverge 
smoothly (Fig. 2a, b). 
Surgical intervention 
The indication for surgery was not given in the 
collected ata, but the dominance of aortoiliac recon- 
struction suggests that most operations were per- 
formed because of intermittent claudication. The 
patients operated on for a femorodistal reconstruction 
would have had either disabling claudication or 
critical ischaemia. The predominant interventions, 
both as first events (68%) and in total (60%), were for 
reconstructive surgery. Only three of the 46 diagnosed 
(non-insulin dependent) diabetic patients required 
surgery. Patients with mild or moderate hyperglycae- 
mia at entry appeared no more likely to require 
surgery than normoglycaemics (Table 4). Only one of 
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Table 2a,b. Repetitive surgery* on the same leg(a) Intention-to-treat population 
Patients urgery-free 
before study period 
Placebo Tidopidine 
Patients urgery-free 
before study period 
Placebo Ticlopidine 
Total Patients 232 236 
Patients having no (further) surgery 209 220 
1 operation 26 15 
2 operations 4 5 
3 operations 1 1 
4 operations 0 0 
5 operations 1 0 
> 5 operations 1 1 
Total legs operated 33 22 
Total operations carried out 49 43 
109 
77 




















before study period 
Patients urgery-free 
before study period 
Placebo Ticlopidine Placebo Ticlopidine 
Total patients 230 231 109 110 
Patients having no (further) surgery 209 220 86 94 
Number of Operations 
1 operation 25 11 28 18 
2 operations 2 2 7 2 
3 operations 1 1 0 1 
4 operations 1 0 1 1 
5 operations 1 0 0 0 
> 5 operations 0 1 1 0 
Total legs operated 30 15 37 22 
Total operations carried out 41 33 53 29 
* Surgery types 1,2,3,4 and 6 only. 
Table 3. Risk ratios a derived from full cox model risk for proximal 
leg artery surgery b during period 
Covariate Intention-to-treat On-treatment 
Gender Female/Male 0.68 (0.38-1.20) 
Age (year on year) 1.03 (0.99-1.06) 
Blood pressure H/M/L 0.89 (0.67-1.17) 
Cholesterol H/M/L 1.11 (0.87-1.41) 
Triglycerides H/L 1.28 (0.79-2.06) 
Glycaemia H/M/L 0.96 (0.66-1.40) 
White cells 1.01 (0.88-1.14) 
Smoking C/F/N 1.52 (0.95-2.44)2 
Duration PAD L/M/S 











1.08 (0.78-1.49) 1.01 (0.68-1.50) 
2.60 (1.66-4.08)*** 2.66 (1.53-4.62)** 
0.74 (0.44-1.23) 0.69 (0.35-1.35) 
0.41 (0.26-0.64)*** 0.43 (0.24-0.76)* 
Ratios given are the relative risks between contiguous strata (rate 
for nth stratum/rate for n + lth stratum). ~ Types 1 and 2 operations, 
only.*p = 0.0035;**p = 0.0005;***p = 0.0001;tp = 0.055;:~p 
= 0.082Intesnsity of covariates: blood pressure: L systolic ~ 140 and 
diastolic ~ 90, M systolic > 140 or diastolic > 90, H systolic > 165 
or diastolic > 105 mmHg; Cholesterol: L < 6.2, M 6.2- _< 6.5, H > 
6.5 retool/l; triglycericles: L < 2.2, H ~ 2.2 mmol/1; glycaemia: L < 
5.8, M 5.8 - < 6.7 H a 6.7 mmol/1; white cell count: risk increment 
for increase of 1.0x109/1 in count; smoking: current/former/never; 
duration of peripheral rterial diseases: 1 > 3 years, M 1-3 years, S 
< 1 year; Y, covariate factor present (previous lower limb vascular 
surgery, evidence of ischaemic heart disease: IHD), N, covariate 
factor absent, T, ticlopidine; P,placebo. 
the diabet ic  pat ients  underwent  amputat ion  com- 
pared  to 13 of the non-d iabet ics  (2.0%). For  one pat ient  
an amputat ion  dur ing  the s tudy  was  the on ly  vascu lar  
surgical  event,  whi le  another  had  had  a sequence of 
operat ions  before ent ry  wh ich  cu lminated  in amputa -  
t ion as the first and  on ly  s tudy  event: both  pat ients  
surv ived  beyond the end of the study. Seven pat ients  
had  thrombectomy as a first event  in the s tudy  per iod  
but  this a lways  fo l lowed pre -s tudy  reconstruct ive 
surgery  on the same leg. The interval  between 
reconstruct ion and  thrombectomy could  be as great  as 
10 years. On one occasion thrombus  had  spread  into 
the contra latera l  leg vessels. On all except one occa- 
sion, type 4 operat ions  fo l lowed pr ior  reconstruct ive 
surgery  to the same leg (or a b i latera l  graft): the 
except ion was  a thromboendar terectomy.  Type 4 
operat ions  had  either no par t icu lar  re lat ion to the 
patency  of the other  operat ions  (pseudoaneurysm 
resections, w i th  or w i thout  patch ing- -7 )  or were 
at tempts  to deal  w i th  inadequate  b lood  f low in ear l ier  
reconstruct ive surgery  (eight th romboendar terecto -  
mies,  two  percutaneous  t rans lumina l  angioplasf ies,  
six instances of re-graf t ing (with PTFE) and  two of 
repa i r  or  patch ing  of faul ty  anastomoses) .  In one case 
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an infected and fibrosed graft segment was removed. 
Only seven patients underwent non-leg peripheral 
vascular surgery: four carotid endarterectomies, one 
with Dacron patch, and three operations for occlusive 
renovascular disease. Five of these patients had no 
other vascular surgery, one had prior aortobiiliac graft 
and the seventh a subsequent single amputation. Only 
one patient underwent coronary artery surgery: the 
patient also underwent both prior and subsequent leg 
artery surgery. 
Discuss ion  
This study was the first Secondary prevention trial of 
any intervention i  the field of atherosclerotic disease 
to show a convincing reduction of overall mortality 
(29% lower in the ticlopidine group), a reduction 
which is precisely accounted for by the reduction of 
vascular deaths. These results are consistent with the 
now well known effect of antiplatelet agents in 
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Fig. 2. Survival plots from the Cox models howing the estimated 
proportions of patients (ordinate) who had not undergone l g 
vascular surgery (Types 1, 2, 3, 4 or 6) at each time after 
randomisation (abscissa), adjusted for risk factors. (a) All events 
occurring up to the determined end of study medication 
(31.12.1987) orprior death--intention-to-treat an lysis). (b) Events 
occurring and patients at risk only while taking study medication 
(on-treatment a alysis). 
cardiac and cerebral circulations when there is already 
clear evidence of atheromatous arterial disease. 4-7 The 
present paper confirms that treatment with ticlopidine 
also results in a 50% decrease in the requirement for 
surgical reconstruction of diseased arteries in the legs 
from the aortic bifurcation downwards. As with the 
reduction in vascular mortality (and vascular events), 
the effect is immediate, sustained and uniform over 
the whole treatment period of up to 7 years. 
The study population had an increased preva- 
lence of acknowledged risk factors for peripheral 
arterial disease compared to their peers in the general 
population, z°These fac tors -  hyperglycaemia, hyper- 
tension, hyperlipidaemia, evidence of ischaemic heart 
disease, male sex and tobacco use- -are  also generally 
accepted as risk factors for development of coronary 
and/or  cerebral arterial disease. However, in an 
analysis of this study population for risk factors for 
vascular thrombotic events only age, sex, identified 
ischaemic heart disease, hyperglycaemia, smoking 
and white cell count appeared to be important 
predictors of an event. This was interpreted as 
suggesting that, since the risk factors are different, the 
mechanisms for development of atherosclerotic dis- 
ease and for the subsequent occurrence of acute 
thrombotic events are different, an obvious but rarely 
articulated point. 
These risk factors have not been studied in the 
same population and study period in relation to the 
risk of requiring leg vascular surgery. Only previous 
leg vascular surgery was strongly and significantly 
predictive of the need for further surgery, a reversal of 
its (non-significant) protective influence on acute 
thrombotic events. This mirrors the pattern for ischae- 
mic heart disease, which in this population showed a 
strong predictive effect for (the predominantly car- 
lo  diac) acute thrombotic events but which now 
appears mildly protective for surgery, though not 
significantly so. It is possible that this is because 
ischaemic heart disease imposes limitations in daily 
physical activities uch that the limitations from leg 
ischaemia re not obvious to the point of triggering a
requirement for surgery. The duration of peripheral 
vascular disease has no predictive power for either 
type of outcome vent. 
The overall risk for surgery appears unrelated to 
both glycaemia nd white cell count in contrast o the 
strong predictive power of each of these factors for 
acute thrombotic events. There is no evidence in this 
study that mild or moderate hyperglycaemia give any 
differential risk for surgery affecting blood supply 
below the groin (type 2 operation) compared to above 
the groin (type 1--Table 4). Insulin-dependent dia- 
betics (who are prone to microvascular disease leading 
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Table 4. Surgery and glycaemia 
Normoglycaemic patients ~ Hyperglycaemic patients a 
Placebo Ticlopidine Placebo Ticlopidine 
Total patients 273 280 49 49 
Type 1 surgery - -  aortofemoral region: number of operations 29 13 4 2 
Type 2 surgery--femorodistal region: number of operations 10 5 2 1 
a Fasting blood glucose as measured at study entry: normoglycaemic - fasting blood glucose < 5.8 mmol/1; hyperglycaemic - fasting blood 
glucose a 5.8 mmol/1. Five events of types 1 or 2 were recorded for the 36 patients for whom a pre-study fasting glucose value was not 
recorded. 
to ulceration, gangrene and amputation) were 
excluded from the study: non-insulin-dependent dia- 
betics did not appear to be more susceptible than non- 
diabetics to conditions leading to amputation. The 
finding that tobacco use increases the risk for surgery, 
while not reaching significance, is consistent with 
previous tudies. In the U.S. Physicians' Health Study 8 
both past and current smoking were very strong risk 
factors for the need of leg peripheral vascular surger~ 
as they were in an earlier study of claudicants. ~3 
The estimates of effect of female gender on 
surgery risk, while less than the effect on thrombosis 
risk, are of consistent magnitude, suggesting that 
significance might be revealed in a larger study which 
included more women. Similarly, age might be 
revealed as a significant predictor in a larger study 
with more outcome vents. In contrast, the influences 
of blood pressure, lipidaemia nd duration of periph- 
eral arterial disease on the risks for surgery and 
thrombosis appear about the same and minimal with 
the exception of a near significant risk in OTT analysis 
from raised triglyceride. The present findings are 
almost entirely consistent with those of Hess and co- 
workers 9 that diabetes and lipidaemia are not pre- 
dictive of the progression of occlusion of the leg 
arteries whilst smoking is: s3 there is disagreement 
over the role of hypertension. 
The effect of ticlopidine on reducing the need for 
first-time surgery at first sight appears not to be 
clearly reflected in an equivalent reduction in the need 
for further vascular surgery. However, the numbers of 
legs undergoing multiple operations was small (seven 
legs each in the placebo and active groups for patients 
who had not had prior leg vascular surgery and 12 
and 7 legs in the placebo and active groups who had, 
respectively. On the other hand, all those patients who 
had had leg vascular surgery before starting treatment 
could be regarded as eligible for re-operation: here 49 
and 29 legs were re-operated in the placebo and active 
groups, respectively. The benefit of ticlopidine treat- 
ment, started even after previous urger36 seems clear 
although because of the confounding of legs and 
patients, it was not possible to make a formal 
statistical evaluation. 
The clear and important benefit from ticlopidine 
treatment found in this study is consistent with that 
found for other antiplatelet treatments. 8'9 The fact that 
the benefit effectively begins on starting treatment 
might suggest that the effect is a purely antithrombotic 
one since other interventions to slow or reverse 
atheroma progression (e.g. on cholesterol or smoking) 
appear to require many months before an effect on risk 
becomes evident. However, it is generally acknowl- 
edged that platelets are intimately involved in plaque 
enlargement even in the absence of occlusive throm- 
bosis. The platelet activities involved may be only a 
part of those which lead to catastrophic occlusive 
thrombosis, e.g. adhesion to subendothelium and the 
release reaction. The present findings point to the 
general conclusions that modification of platelet reac- 
tivity may be clinically very significant in slowing the 
progression of atherosclerotic disease and that, by 
implication, platelets are indeed involved in the 
progression of atheromatous plaque. 
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